Although the results of the few studies in pediatric age on the cardiovascular effects of GH therapy are reassuring, this topic is of major clinical interest since the unlimited supply of biosynthetic GH (rh-GH) has led to increased dosage in the treatment of short stature. We have therefore assessed echocardiographic evaluation during short and medium-term rh-GH administration in 24 short children, irrespective of their GH secretory capacity. Nineteen age and sex-matched normal control subjects were also examined. Doppler echocardiographic evaluation of systo-diastolic cardiac function was performed before and at 1, 3, 6, 12 months of rh-GH therapy at standard dosage (average: 0.87 ± 0.07 UI/Kg/week). No differences between control children and patients before treatment were found. No alterations in LV morphology or systo-diastolic function have been observed in short children throughout hormone therapy. In conclusion, in GH-treated children there was no increase in risk factors known to be associated with cardiovascular morbidity. Extensive and longer follow-up studies will be required to confirm the safety of chronic rh-GH treatment.
|Translated title of the contribution||Echocardiographic monitoring in short children treated with growth hormone|
|Number of pages||6|
|Journal||Rivista Italiana di Pediatria|
|Publication status||Published - Feb 1997|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health